Tahl Cindy's Form 4 filing
Fate Therapeutics Inc (FATE) · filed Oct 4, 2021
- Accession no.
- 0001209191-21-058930
- Filed
- Oct 4, 2021
- Trade date
- Oct 1, 2021
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 4 non-derivative transactions and 1 derivative transaction. Open-market sales total $2.94M. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Tahl CindyCIK 0001655472 | Officer (General Counsel and Secretary) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 1, 2021 | Common Stock | MOption exerciseAcquired | +50,000 | $6.55 | +$327,500 | 158,048 | Direct | |
| Oct 1, 2021 | Common Stock | SSaleDisposed | −16,312 | $58.03F2 | −$946,585.36 | 141,736 | Direct | |
| Oct 1, 2021 | Common Stock | SSaleDisposed | −21,844 | $58.96F3 | −$1,287,922.24 | 119,892 | Direct | |
| Oct 1, 2021 | Common Stock | SSaleDisposed | −11,844 | $59.68F4 | −$706,849.92 | 108,048 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 1, 2021 | Common Stock | MOption exerciseDisposed | −50,000 | $0.00 | $0 | 116,643 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Represents the weighted average sale price of the shares sold ranging from $57.41 to $58.36 to per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in footnotes 2 through 4.
Referenced by the price of 1 transaction in Table I.
- F3
Represents the weighted average sale price of the shares sold ranging from $58.45 to $59.44 per share.
Referenced by the price of 1 transaction in Table I.
- F4
Represents the weighted average sale price of the shares sold ranging from $59.45 to $60.07 per share.
Referenced by the price of 1 transaction in Table I.